W e hold the view that high-density lipoproteins (HDL) are important biological entities that protect against atherosclerosis and cardiovascular disease (CVD). However, HDL is not simply a carrier of cholesterol taken from cells for redistribution and removal from the body, but rather HDL is a complex constellation of many proteins and phospholipids with diverse physiochemical properties and metabolic actions. These proteins are organized into HDL subspecies, a lipoprotein particle system just starting to be understood in terms of structure, function, and relationship to disease. [1] [2] [3] [4] [5] [6] The view that HDL participates in fundamental biological processes that are relevant to health powers a large research effort by many colleagues. The question is how can new information on HDL quality and function be tested in relation to risk of CVD and how can HDL functions be converted into clinical tests that assess future CVD or can be used in the evaluation of new drug developments? In this article, we approach this question by first reviewing HDL structure and metabolism, emphasizing new developments that modify long-held concepts of reverse cholesterol transport. Implicit in use of HDL cholesterol as a predictor of CVD is the expectation that the concentration of HDL cholesterol coincides with antiatherogenic metabolic pathways that are effective in reverse cholesterol transport and hence prevention of atherosclerosis. Failure of treatments that increase HDL cholesterol to reduce incidence of CVD 7-12 suggests that parts are missing in our understanding of HDL metabolism and how it connects to HDL cholesterol concentration and closely related measurements, such as apolipoprotein A1 (ApoA1) and HDL particle number (Table) . Please see http://atvb.ahajournals.org/content/ atvb-focus for all articles published in this series.
experiences a higher cholesterol content than optimal for cellular functions, it must transfer excess cholesterol to the outside, a process called cholesterol efflux. This is accomplished by a lipoprotein system in which HDL is a main actor, interacting with cellular cholesterol transporters, partly independent of and partly engaging with the apolipoprotein B (apoB) lipoproteins, chylomicrons, very-low-density lipoprotein, and low-density lipoprotein (LDL). [13] [14] [15] [16] [17] HDL is a particle composed of a coat of phospholipid surrounding a core of mainly esterified cholesterol. Most HDL in plasma is spherical, in a size range accommodating substantial variation in its cholesterol content. The larger the HDL particle, the more cholesterol ester it has. About 10% of HDL is discoidal, having minimal amounts of cholesterol ester. HDL has proteins on its surface which carry out various biological functions. The main protein on HDL is apoA1 that lends structural stability to the particle and stimulates efflux of cholesterol from cells to HDL, enlarging the particles. Protein molecules other than apoA1 could influence size and form of HDL. [18] [19] [20] [21] [22] [23] Finally, the phospholipid in the HDL coat has biological activity that can be potent. 24, 25 Overall, HDL is a vast system of particles heterogeneous in size, shape, and amount of cholesterol and in type of proteins and phospholipids. HDL carries out diverse functions, which pertain to atherosclerosis but also has other biological actions, such as hemostasis, inflammation, antioxidation, and innate immunity. HDL, identified by the presence of apoA1 and a size range, circulates in plasma for 2 to 4 days. Cholesterol taken up by HDL is delivered to the liver for excretion in the bile, 17 to the intestine for transintestinal cholesterol efflux, 26 and to organs that make steroid hormones from cholesterol. This movement of cholesterol from cells to HDL redistributes cholesterol among tissues. Some of it is excreted by the liver into the bile, and this process is often called reverse cholesterol transport, using intricate molecular machinery shown in studies mainly in mouse models and in cell culture. Protection against atherosclerosis by reducing macrophage cholesterol content in the vasculature thus might be viewed as an epiphenomenon of the general need to regulate cellular cholesterol.
Each HDL particle could have several functions or a focused role via functional speciation. Although we view cholesterol export and transfer as a central feature of HDL metabolism, these other functions could have been involved in the evolution and persistence of the HDL system. Apolipoprotein L1 is an example of an HDL-associated protein that has an established function to destroy trypanosomes and is, therefore, also called trypanosome lytic factor. 27 In general, we still do not know which of the many proteins and functions of HDL have a meaningful relation to CVD and other diseases.
There is even divergence in the definition of HDL. Traditionally, HDL is defined as a lipoprotein that contains apoA1 but not apoB. This is reasonable from the perspective of reverse cholesterol transport because apoA1 is the most effective apolipoprotein in stimulating ABCA1-mediated cholesterol efflux from cells. An alternative definition is simply that HDL is a protein-phospholipid complex in a specified size range smaller than the apoB lipoproteins. 23 Any protein-lipid complex can satisfy this definition. This concept is just being explored, and we do not know how it yet pertains to HDL function and relation to disease. Nonetheless, the distribution of the HDL proteome among sizes is similar for HDL prepared by presence of phospholipid 23 or apoA1. 21
HDL Reverse Cholesterol Transport:
Can It Be Measured?
Several research groups have accomplished steps to establish a method to measure flux of cholesterol from cells into HDL and out of the circulation in vivo. [28] [29] [30] [31] Because HDL size is determined mostly by its cholesterol ester content, size expansion indicates cholesterol uptake and esterification, and size contraction indicates net transfer of cholesterol to apoB lipoproteins and to liver and intestine where it may leave the body or be resecreted into the circulation. The flux rate of HDL clearance from the circulation is another component of cholesterol excretion and reverse cholesterol transport. Each of these 3 reverse cholesterol transport fluxes can be measured by apoA1 flux from small to large HDL, large to small HDL, and irreversible HDL removal. 32 These measurements are obtained from metabolic tracer studies that endogenously label apoA1 in HDL. Another approach is to inject radiolabeled cholesterol nanoparticles and follow their transport into HDL, to apoB lipoproteins, and fecal excretion. 31 These studies are not suitable for large-scale clinical use. But they could be used to vet treatments that are designed to improve reverse cholesterol transport, such as cholesterol ester transfer protein (CETP) inhibitors or LCAT agonists. Ideally, as data accumulate, a steady-state HDL measurement might be found suitable to represent reverse cholesterol transport flux. Knowing how HDL is metabolized as it circulates over days is indispensible to understanding how HDL conducts the process of reverse cholesterol transport and to identify biomarkers. More fundamentally, the concept of reverse cholesterol transport needs to be validated against atherosclerosis and CVD-a goal thus far elusive.
Revising Our Understanding of the Physiology of Human HDL
The canonical model of HDL metabolism, illustrating reverse cholesterol transport ( Figure 1A) , begins with secretion of a small discoidal protein-phospholipid complex, ≈7 nm, called pre-β-1, because of its migration on 2-dimensional In prospective studies in participants free of CVD, HDL that has apoC3 is adversely associated with CHD. In contrast, HDL lacking apoC3 is strongly inversely associated with risk of CHD, more so than the total HDL. Concerning type 2 diabetes mellitus, HDL containing apoC3 is not associated, whereas HDL lacking apoC3 is associated with lower incidence It is hypothesized that the tremendous compositional heterogeneity of the HDL proteome reflects many subspecies of HDL with differential antithrombotic, anti-inflammatory, and antioxidant effects depending on the associated proteins. gel electrophoresis. Pre-β-1 has been the hypothesized nascent particle that interacts at the cell surface of peripheral tissues, such as macrophages to activate cholesterol efflux, and then progressively expands with the transferred cholesterol to larger spherical HDL known as α 3, 2, and 1 HDL in ascending size ranges. These large HDL transfer their cholesterol esters to hepatocytes by mechanisms that include SR-B1 or to apoB lipoproteins using CETP, regenerating a smaller HDL that repeats the process. Eventually, HDL are cleared with their cholesterol load by holoparticle uptake by the liver 33 and the intestine by transintestinal cholesterol efflux. 26 Surprisingly, this straightforward metabolic pathway had not been demonstrated in vivo in humans although it is inferred from studies of infusion of partially delipidated HDL in monkeys, some of which is converted to larger HDL, in vivo. 34 Finally, recombinant LCAT infusion in humans increased conversion of small to large HDL, consistent with reverse cholesterol transport. 35 We developed a method to study HDL metabolism in vivo across its 4 main size subfractions, pre-β-1, α3, α2, and α1, expecting to establish in humans this canonical model. 32 Instead, the data compelled us toward a model of HDL metabolism that requires secretion into plasma of all sizes of HDL simultaneously which circulate mainly within their secreted size for 2 to 4 days before they are cleared ( Figure 1B) . These findings are supported by many reports that cultured cells secrete HDL in a wide range of sizes with no evidence of precursor-product relationships. [36] [37] [38] [39] [40] [41] [42] [43] [44] Cynomolgous monkeys secrete a range of sizes of HDL. 34, 45 We identified size expansion as a minor pathway that connects pre-β with α 2 and α1. 32 Contraction of HDL, perhaps as a consequence of particle fusion and remodeling, could be identified only from α3 to pre-β. Therefore, much of the metabolism of HDL occurs within specific relatively stable size ranges. When it is large, it can deliver its cholesterol ester to the liver by holoparticle or selective uptake. B, In the new model described in Mendivil et al, 32 the liver secretes all sizes of HDL that circulate for 2 to 3 d, not changing in size category, and then are cleared by the liver. Medium size HDL (a3) additionally undergoes size contraction and remodeling to become pre-β HDL. Minor metabolic pathways depict size expansion of pre-β and a3 HDL to large (a2) and large (a1) HDL. ApoA indicates apolipoprotein A.
Implications of New Metabolic Pathways for Reverse Cholesterol Transport and for HDL Infusion Therapy
These findings provoke fundamental questions about the function of HDL. First, if HDL is secreted throughout its size range, and mainly remains within the secreted size range as it circulates, then how does reverse cholesterol transport take place? One possibility stems from the structure of spherical (α) HDL which includes 4 or 5 apoA1 molecules arranged as a trefoil. 46 The trefoil can twist and untwist, contracting and expanding the HDL particle, altering its core cholesterol ester content. Trefoil models allow about a 1-nm diameter range, representing about a 10% change. Figure 2 shows sizes of LpA-I (HDL that contains apoA1 but not apoA2) that each have 4 molecules of apoA1. The trefoil permits cholesterol transfers in and out of HDL but does not change a size category, such as from α-2 to α -1. Preliminary results suggest that 2 molecules of apoA2 can substitute for 1 molecule of apoA1 to preserve the trefoil (WS Davidson, communication), important because 60% to 70% of HDL has both proteins. Alternatively, or in addition, size expansion and contraction between conventional size categories could be done by HDL subspecies that contain proteins that stimulate cholesterol efflux and particle expansion. Our ongoing work is identifying HDL containing apoE, a subspecies comprising a minority of total HDL, 5 that engages size expansion as a major pathway (Morton AM et al, presented at ATVB, 2016) as suggested by studies in vitro. [47] [48] [49] [50] Second, for what purpose does the liver and intestine secrete cholesterol-rich HDL? Secretion of large HDL could be another means by which hepatocytes and enterocytes regulate their cholesterol content because size of nascent HDL depends on the amount of cholesterol and phospholipid in domains in the endoplasmic reticulum and plasma membrane that are recruited by ABCA1 in HDL assembly and secretion. 36 Proteins other than apoA1 tend to be localized in part, not all, of the size range of HDL, some involved in lipid and lipoprotein metabolism and others having other functions, such as in thrombosis, inflammation, and oxidation ( Figure 3 ). 21, 23 Some of these proteins are secreted into plasma on apoA1 containing HDL at the same time as apoA1 secretion rather than formed while circulating in plasma. 21 Structurally, the subspecies may need a certain size to accommodate specific proteins, essentially the protein component driving the size of the secreted particle.
Third, the hypothesis that reverse cholesterol transport occurs within the larger HDL sizes downgrades the uniqueness of pre-β-1 as the nascent HDL particle that fills with and empties cholesterol to perform reverse cholesterol transport. Trials to date of HDL pre-β infusion therapy have failed to reverse coronary atherosclerosis 51, 52 although additional trials of variations of pre-β HDL are in progress. 53 We note that the early trial of infusion of ApoA1 Milano pre-β HDL particles, reported in 2003, widely viewed as delivering positive results, was actually a negative trial. 52 The positive interpretation came from analyzing change from baseline in percent atheroma volume in just the treated group using a paired test. But the valid test in a randomized clinical trial is a 2-sample test that compares change in the HDL infusion group to that of the control group. The P value for that test, reported in the article, was far from statistically significant, P=0. 29 . The default interpretation of this circumstance is that the therapy is not effective. It is also possible that the trial was inadequately powered, which would require a follow-up trial with a larger sample. The future of HDL infusion therapy may venture to larger size HDL subspecies that have specific proteins in addition or in place of apoA1 that stimulate steps in reverse cholesterol transport.
HDL Biomarkers to Predict CVD: Is There as Yet a Causal Biomarker? HDL Cholesterol, ApoA1, and Particle Number
HDL cholesterol and apoA1 concentrations are both inversely associated with risk of CVD in large, prospective studies of individuals free of existing CVD. 54 Importantly, the 2 measures for HDL are strongly correlated (P=0.8 or greater), suggesting that for the most part that the cholesterol and apoA1 concentrations reflect the same thing and show somewhat similar associations with risk of CVD. In the prospective EPIC-Norfolk study of individuals free of existing CVD, the relative risk of coronary heart disease (CHD) per SD higher HDL cholesterol was 0.78 (95% CI: 0.70-0.87) and for apoA1 it was 0.79 (95% CI: 0.71-0.87) in models adjusted for age, sex, smoking, body mass index, and alcohol intake. 55 However, additional adjustment for other lipid markers, such as LDL cholesterol, triglycerides, or mutual inclusion of HDL cholesterol and apoA1 in the same model, can influence the strength of these associations, and the association of apoA1 may be more robust than HDL cholesterol to such comprehensive model adjustments. 55 Furthermore, HDL cholesterol may not have a completely linear association with CHD risk because the pattern of the association seems to reach a plateau at high HDL cholesterol levels (>75 mg/dL for men and >90 for women). 55, 56 HDL particle concentration (sometimes called particle number or HDL-P) can be estimated by nuclear magnetic resonance spectroscopy, which analyzes the lipid signals of HDL size populations. Plasma apoA1 is highly correlated with HDL particle number (r=0.74), 57 but the majority of studies compare HDL-P to HDL cholesterol and not with apoA1 concentrations. Studies that include association analyses of both HDL cholesterol and HDL-P have highlighted some important considerations. For instance, in the MESA study, HDL cholesterol and HDL-P were similarly associated with 65% lower risk of CHD among those in the top quartile compared with the lowest quartile. However, when mutually adjusted, only HDL-P remained inversely associated with risk of CHD. 58 In the Dallas Heart Study and the Women's Health Study, HDL cholesterol and HDL-P were slightly less correlated (r=0.52 and 0.47, respectively). 57, 59 In the Dallas Heart Study, HDL-P was significantly inversely associated with cardiovascular events even after adjustment for HDL cholesterol. 59 HDL cholesterol trended toward an association with cardiovascular events, which became null after adjusting for HDL-P. However, it should be mentioned that there were only 132 events in the study, making conclusions from this type of complex multivariable analysis insecure. In contrast, in the Women's Health Study, HDL cholesterol was more strongly inversely associated with CHD risk than HDL-P in the multivariable-adjusted models. 57 Unfortunately, the adjusted relative risk for apoA1 with risk of CHD was not reported.
HDL cholesterol and HDL-P have also been compared across race and ethnic groups. Interestingly, black men have been reported to have higher HDL cholesterol levels compared with nonblack men, whereas such differences were not observed for HDL-P. 60 In this study, HDL-P was strongly inversely associated with risk of CHD in both blacks and nonblack participants, whereas HDL cholesterol was statistically significant only in nonblacks.
In summary, complex considerations of study design, multivariable modeling choices, and measurement error in the assessment of HDL cholesterol, HDL-P, and apoA1 must be encumbered when discussing the extent to which any of the measures are superior in their capacity to reflect the cardioprotective functions of HDL and prediction of CVD.
HDL Concentration May Not Indicate Effective Reverse Cholesterol Transport
If HDL concentration indicates a causal relationship to CVD, then HDL should perform reverse cholesterol transport more effectively as its plasma concentration increases. But this supposition seems counterintuitive from a metabolic standpoint. The first step of reverse cholesterol transport, transferring cholesterol from cells to HDL, which would increase HDL cholesterol concentration, needs to be paired with an equal or stronger second step to transfer the cholesterol in HDL to the liver, directly or via apoB lipoproteins, which would decrease HDL cholesterol concentration. Carrying the argument further, a low HDL cholesterol concentration could reflect better reverse cholesterol transport than a high HDL cholesterol level if it reflects a steady state of fast removal of cholesterol obtained from cells by HDL. Indeed, the SR-B1 mutation, reducing selective uptake of cholesterol from HDL by the liver, is associated with higher HDL cholesterol and higher CVD prevalence. 61 Conversely, CETP inhibition increases the concentration of HDL cholesterol but has had no effect or actually increases CVD. [7] [8] [9] However, the most recent trial of CETP inhibition, conducted in >30 000 patients with CVD who were receiving intensive statin therapy, found that the group treated with CETP inhibitor, anacetrapib, achieved 43 mg/dL higher HDL cholesterol than the placebo group, and the rate ratio for an coronary event was 9% lower (0.91; 0.85-0.97). 10 As intriguing as this new finding is for the promise of HDL cholesterol drug treatments, in order for the trial results to fully support the concept that HDL cholesterol (or apoA1 or HDL-P concentrations) are indicative of reverse cholesterol transport, the relative difference in HDL cholesterol levels of 104% between treatment and placebo group should have reflected a much greater difference in coronary event risk. In addition, anacetrapib decreased LDL cholesterol by 41%, which could have accounted for most if not all of the reduced risk of CVD. A recent genetic study suggested that the mechanism by which CETP inhibition affects CVD is in its effects on apoB lipoproteins rather than on HDL. 62
HDL and Triglyceride-Rich Lipoproteins
Often mentioned is the hypothesis that HDL cholesterol predicts CVD only because it is a marker for plasma triglycerides and atherogenic triglyceride-rich apoB lipoproteins. There is less intraindividual biological variability in HDL cholesterol than triglycerides, which would favor a stronger relationship with CVD for HDL cholesterol than triglycerides. However, although there is a moderate inverse correlation between HDL cholesterol and triglyceride concentrations, for example, −0.40 in the Women's Health Initiative cohort, 57 the correlation between triglycerides and apoA1 concentration is weaker (−0.09), but nonetheless apoA1 is as strong or stronger predictor of CVD risk as HDL cholesterol. Adjustment for triglycerides does not eliminate the significant association of HDL cholesterol with CVD. Thus, it seems unlikely that atherogenic triglyceride-rich apoB lipoproteins account for the increased risk associated consistently with low HDL cholesterol. Just like HDL, the apoB lipoproteins exist in subspecies based on proteins, such as apolipoprotein C3 (apoC3) or apoE, and many others. These subspecies differ in metabolism [63] [64] [65] and in relation to CVD. 66, 67 It remains possible that a low HDL cholesterol concentration is a biomarker for an especially atherogenic very-low-density lipoprotein or LDL subspecies.
Why then are HDL cholesterol, apoA1, and HDL-P such strong and independent predictors of CVD? Our hypothesis is that HDL ordinarily contains ≥1 antiatherogenic components, subspecies, or functions that track with its plasma concentration but are not affected by HDL cholesterol raising treatments or mutations that do not target the protective factors. In this framework, HDL cholesterol, apoA1, and HDL-P are biomarkers for causal antiatherogenic components or traits in HDL, but to date treatments are misdirected.
HDL Size
Associations between HDL size and CVD vary depending on the method used to determine HDL size. Some studies have shown that levels of large HDL are inversely associated with CHD, 68, 69 but other studies have found that levels of both large and small HDL predict reduced CHD incidence [70] [71] [72] or that HDL size determination does not improve CHD risk prediction beyond that provided by HDL cholesterol or apoA1 measurements. 55, 73 In addition, high levels of the small pre-β1 HDL have been identified in patients with CHD, but pre-β1 HDL did not independently predict CHD in models that included the large α-1, which was the independent predictor among the sizes. [74] [75] [76] Adjustment for LDL cholesterol concentration may affect the relationship of HDL size to CVD. HDL is a complex family of lipoproteins which may not result in the same constellation of subspecies when isolated according to different methods. For example, a large size HDL prepared by size exclusion chromatography does not have the same population of subspecies or components as a large HDL prepared by ultracentrifugation. 77 Presently, HDL size has not been convincingly demonstrated to aid in either risk prediction or the evaluation of HDL-raising treatments. 55, [70] [71] [72] [73] 75, 76 Furthermore, it is not intuitively clear that a preponderance of large or small HDL reflects strong or weak reverse cholesterol transport. Finally, antithrombotic, anti-inflammatory, and antioxidative proteins each localize in a portion of the overall HDL size range that may be affected by preparation techniques (Figure 3 ). 21, 23, 77 
Genetic Variation Affecting HDL Cholesterol (Mendelian Randomization Studies)
Epidemiological studies that have explored the risk of CVD events among carriers of genetic variants that are associated with lifelong differences in HDL cholesterol levels have generally not found lower risk of CVD among individuals that are genetically predisposed to the high HDL cholesterol levels. 61, 78 These Mendelian randomization studies are more often derived from genome-wide association studies that have identified many genetic loci that are associated with HDL cholesterol or apoA1 levels. [78] [79] [80] [81] Of hundreds of identified single nucleotide variants, a genetic risk score is then compiled after limiting this to single nucleotide variants that have exclusive effects on HDL cholesterol, that is, no association with triglycerides or LDL cholesterol. These studies consistently report that the genetically determined HDL cholesterol is not associated with risk of CAD. [78] [79] [80] [81] Limitations for these genetic observation studies include the summation of a high number of genetic variants for which we have only little knowledge about their function. We may argue that because of the complexity of HDL metabolism, we should sum variants from different loci to capture the biology. However, as each variant explains only little of the variation in HDL cholesterol levels, and the complexity of HDL metabolism involves interactions with both triglycerides and LDL cholesterol (ie, most genetic variants will exert pleiotropic lipid effects), restricting to genetic variants with an exclusive HDL cholesterol association may miss some of the most important functional aspects of the HDL pathway.
Furthermore, the Mendelian randomization approach, having thus far focused on HDL cholesterol or apoA1 levels, may not capture the functional properties of HDL that play a role in the disease pathology. In fact, the clear null findings in Mendelian randomization studies of HDL cholesterol may be considered another strong argument for the continued investigations into the complexity of the protein and phospholipid constellation that makes up HDL. In contrast, Mendelian randomization studies of LDL cholesterol, which is more simply defined by a single apoB protein per particle, have been strong and straightforward in supporting the role of LDL cholesterol in atherosclerosis. 78, 79, 81 
Cholesterol Efflux From Cells to HDL: the First Biomarker of HDL Function Predicting CVD
Current HDL research is emphasizing the development and evaluation of assays that reflect functional properties of HDL rather than its plasma concentration. Cholesterol efflux measures the ability of HDL to receive cholesterol from macrophages, remodeling, and enlarging the particles. Cholesterol efflux has been measured in several epidemiological settings.
In cross-sectional studies, the capacity of HDL to stimulate cholesterol efflux is inversely associated with carotid intima-media thickness 82 and with prevalent coronary artery disease. 82, 83 However, because the measurement of cholesterol efflux occurred after the CVD event, the results are prone to reverse causation. Thus, there was an urgent need for studies that followed participants for incident disease. The first such prospective studies were mostly convenience samples of participants that were referred for coronary angiography. In the Cleveland Clinic study, higher cholesterol efflux capacity was paradoxically associated with higher risk of myocardial infarction and stroke, 83 whereas a large study in Austria also of patients that were referred for angiography reported an inverse association between cholesterol efflux and risk of CVD mortality. 84 Beyond reverse causation, the complicated confounder structure in such patient samples where medications for hypercholesterolemia are prevalent make it difficult to interpret and reconcile these results. For example, the lack of association between LDL cholesterol and risk of CVD in the Cleveland Clinic study may hint that considerable residual negative confounding may be obscuring the relationships.
Importantly, 2 prospective studies in populations free of underlying CVD, the Dallas Heart Study and the UK EPIC-Norfolk Study, both found strong inverse associations between cholesterol efflux measured using 2 different methodological approaches (reviewed below) and cardiovascular events, which persisted even when HDL cholesterol was held constant by entering it into the statistical model. 59, 85 However, in the Dallas Heart Study, 59 HDL cholesterol level was not statistically significantly associated with risk of CVD by itself. In the absence of a strong association between HDL cholesterol and CVD, it cannot be expected that adjustment for HDL cholesterol would influence results. When using this approach to judge the superiority of one factor over the other, the precision, biological variation, and predictive value of each measurement are important considerations.
Recently, efflux was studied in a case-control analysis nested in a primary prevention trial of a high potency statin, rosuvastatin 20 mg. 86 Efflux, measured at the start of the trial, was not a predictor of incident CVD in models either adjusted for age and treatment group (odds ratio=0.84; 95% CI: 0.55-1.27) or that added CVD risk factors and LDL cholesterol and triglycerides (odds ratio=0.75; 95% CI: 0.47-1.21). Efflux, measured at 1 year while the participants were taking rosuvastatin, significantly predicted coronary events. However, efflux did not significantly predict coronary events after adjustment for HDL cholesterol, apoA1, or HDL-P measured either at baseline or after 1 year of statin treatment. Change in efflux from baseline to 1 year also was not associated with incident CVD events. In most analyses in this study, HDL cholesterol, apoA1, and HDL-P were significant or near-significant predictors of coronary events, not affected by additional adjustment for efflux.
In summary, the novelty and appeal of HDL-mediated cholesterol efflux, as a predictor of CVD, is that it actually connects HDL with its most widely accepted property. In most studies, HDL cholesterol or another measure of HDL concentration is moderately correlated with efflux (eg, R=0.5-0.6). However, results among several studies as yet do not agree whether efflux significantly predicts CVD independently of concentrations of HDL cholesterol, HDL-P, or apoA1.
Multiple Pathways of HDL-Mediated Macrophage Cholesterol Efflux
Cellular efflux of cholesterol to HDL occurs by both specific receptor-mediated transport (via ABCA1, ABCG1, and SR-BI) and aqueous diffusion. 87 ABCA1 promotes unidirectional cholesterol flux most strongly to lipid-free apoA1 and less well to spherical HDL. [88] [89] [90] ABCG1 and SR-B1 promote cholesterol efflux to spherical HDL but not to lipidfree apoA1. 91, 92 Aqueous diffusion constitutes another major pathway of cholesterol efflux from macrophages 93 and may account for a large subset of cholesterol efflux in vivo. 94 Each of these 4 mechanisms can be studied although only total efflux has been used in epidemiological studies pertaining to prediction of CVD. Total efflux is measured by incubating a mouse macrophage cell line, J774, with plasma from which apoB lipoproteins have been removed. Before incubation with samples, the cells are loaded with labeled unesterified cholesterol and treated with cAMP that upregulates ABCA1. In most but not all studies, the cells are treated with an inhibitor of ACAT to increase further their content of unesterified cholesterol which increases the efflux process. These treatments enhance ABCA1-mediated efflux as a component of total efflux. Cholesterol that effluxed from the macrophages is accepted not only by HDL but also by albumin present in the apoB-depleted sera, which makes the test partly nonspecific to HDL function. 83 Cholesterol efflux from cells to HDL specifically by ABCG1, SR-B1, or passive diffusion has not been studied in relation to future risk of CVD in an observational setting. If our hypothesis is correct, that large size HDL engage in reverse cholesterol transport more so than small discoidal HDL, then ABCG1 and SR-B1 efflux may have an even more important role for atherosclerosis than ABCA1-mediated efflux as the latter only effluxes cholesterol to the small HDL particles.
Fundamental Questions on Cholesterol Efflux
First, the 4 types of efflux have not yet been compared in terms of their respective strength of association with risk of future CVD. The proportion of efflux that occurs through each of the 4 pathways in vitro and in vivo is unknown. In other words, does total efflux, measured in vitro, accurately model what occurs in vivo? Second, does cholesterol efflux explain the strong prediction of CVD by HDL cholesterol? Third, ideally, the efflux property of HDL would be reduceable to a simple compositional measurement in HDL. An HDL test that measures a core function of HDL like efflux could be used widely if it strongly predicts CVD independent of the easily and cheaply measured HDL cholesterol.
HDL Proteins: Subspecies and Proteomics
The tremendous compositional heterogeneity of the HDL proteome reflects our emerging understanding of the diverse functions of HDL. The proteins that are present on HDL have great importance for the downstream metabolism and function of HDL by mediating its interactions with receptors, enzymes, and other proteins. Furthermore, the HDL proteome is modifiable and has been shown to be heavily affected by inflammation such as in CVD and infections. [95] [96] [97] [98] Myeloperoxidase-Oxidized HDL One protein that has been found of importance to HDL's antiinflammatory properties and capacity to accept cholesterol is the immunogenic epitope of myeloperoxidase (2-OH group of Trp72). 99 Thus far, apoA1 with the myeloperoxidase epitope (myeloperoxidase-oxidized HDL) is elevated in patients with CVD. The myeloperoxidase-oxidized HDL subtype is only found at low concentration in human plasma (≈0.007%). Further investigation in prospective studies is warranted to determine its potential as a diagnostic and therapeutic target for CVD.
HDL Containing ApoC3
Ongoing research has also focused on apoC3 as a potentially important protein that may modulate HDL function. ApoC3 is present on 6% to 15% of HDL. The concentration of HDL that has apoC3 is associated with higher, not lower, risk of CHD. 3 (Figure 4A ) In 4 prospective studies of middle-aged participants free of CVD, the relative risk of developing CHD for a period of 10 to 14 years was 0.76 (95% CI=0.70-0.83) for each SD higher HDL lacking apoC3 and 1.09 (95% CI=1.01-1.18) for HDL containing apoC3. The heterogeneity test for difference between these HDL subspecies for CHD risk is significant (P<0.02). The relative risk of CHD per each SD of total HDL cholesterol was 0. 0.80 (95% CI=0.74-0.87). Therefore, the risk of CHD for total HDL cholesterol becomes more inverse (protective) when the harmful apoC3 containing subspecies is removed.
We found that the presence of apoC3 on HDL modifies the association of HDL with risk factors for CHD. HDL containing apoC3 was associated with metabolic risk factors, such as diabetes mellitus, obesity, and blood glucose. In contrast, HDL lacking apoC3 was associated with favorable levels of these risk factors. 3, 5, 100 These findings on HDL apoC3 and CHD were recently extended to the risk of incident diabetes mellitus. Concentrations of HDL containing or lacking apoC3 were differentially associated with risk of diabetes mellitus (P for heterogeneity=0.002; Figure 4B ). 101 The relative risk of diabetes mellitus for top versus bottom quintiles of HDL cholesterol lacking apoC3 was 0.48 (95% CI: 0.27-0.85), P for trend=0.002, whereas HDL cholesterol-containing apoC3 was unassociated with risk (relative risk top versus bottom quintile=1.05; 95% CI: 0.50-2.21; P for trend=0.44). The association with incidence of diabetes mellitus for HDL cholesterol lacking apoC3 was stronger than that for total HDL cholesterol (relative risk=0.60; 95% CI: 0.35-1.03; P for trend=0.04).
These findings on apoC3 demonstrate the importance of the protein cargo of HDL, and the ability to identify functionally distinct subtypes based on it. It may be that HDL subtypes defined on the basis of other proteins may reveal even greater functional differences and potentially lead to early detection of individuals at high risk of cardiometabolic disease.
HDL Lipidome
A vast array of phospholipids comprise the coat of the HDL particle. The type of phospholipid used to reconstitute HDL particles affects its antiatherogenic and anti-inflammatory properties. 25 The organization of specific phospholipids on the HDL surface and interactions with proteins are not well understood. Sphingosine-1-phosphate is a bioactive phospholipid with pleiotrophic effects on endothelial cell migration, nitric acid formation, adhesion molecule abundance, and inflammation. 24, 102, 103 ApoM, a lipocalin on HDL, associates with sphingosine-1-phosphate and serves as a chaperone for its effects on cells. 103 The relationship between apoM and sphingosine-1-phosphate is noteworthy as an interacting pair of protein and phospholipid on HDL. ApoM has a complex relationship to atherosclerosis in diverse mouse models. 24 
Direction for Progress on Finding a Causal Biomarker of Atheroprotective HDL Function
The complexities of HDL metabolism offer a huge challenge to researchers to discover findings important to understand human biology and to develop them into clinical tools. But it should be a welcome challenge. We list some possible directions for research.
1. Kinetic measures of reverse cholesterol transport in vivo, such as size expansion, contraction, and removal from circulation. Actual measures of cholesterol flux itself in reverse cholesterol transport. Although kinetics can be studied only in small samples in tracer metabolism study, kinetic findings could be a reference point for developing and calibrating surrogate biomarkers for HDL reverse cholesterol transport. The obvious advantage to HDL metabolic measurements is that they show what is actually occurring in the human body, without the inherent uncertainty in studies of nonhuman or cell culture systems. 2. Development of a surrogate biomarker for HDL reverse cholesterol transport. Such a biomarker could be total efflux or ≥1 of its 4 components: diffusion, SR-B1, ABCG1, and ABCA1. When we learn to what extent these mechanisms operate in humans, we may be closer to the goal of devising a surrogate which may be calibrated to metabolism in vivo. 3. Search for HDL subspecies that are high effluxers because of specific protein content. These could be steadystate surrogates for efflux. 4. Search for causal components in circulating HDL that explain robust independent CVD risk prediction. 5. HDL subspeciation based on protein or phospholipid content, for example, HDL with apoC3 or apoE. Individual subspecies as risk markers or combination of subspecies into an index. 6. For all of these new biomarkers, there will be a need to develop them into a simple test for HDL function that can be done in a routine clinical laboratory in order for it to be of diagnostic value in the management of patients.
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